Tofacitinib versus oral prednisolone for induction of remission in moderately active ulcerative colitis (ORCHID): A prospective, open-label, randomized, pilot study.
Arshdeep SinghVandana MidhaKirandeep KaurRamit MahajanDharmatma SinghRamandeep KaurAditya KohliAvantika ChawlaKriti SoodNamita BansalAjit SoodPublished in: Journal of Crohn's & colitis (2023)
In patients with moderately active ulcerative colitis, there was no difference in the efficacy and safety of tofacitinib and oral prednisolone for induction of remission at 8 weeks.